ArticleMolecular cancer therapeutics2010
Interstitial infusion of glioma-targeted recombinant immunotoxin 8H9scFv-PE38.
Article in Molecular cancer therapeutics, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 31 citations in OpenAlex.
- Development and characterization of a novel B7-H3 rabbit monoclonal antibody for glioma diagnosis.Frontiers in pharmacology · 2026Article
- Enhanced cytotoxicity of aFrontiers in pharmacology · 2023Article
- ABC Transporter Inhibition Plus Dexamethasone Enhances the Efficacy of Convection Enhanced Delivery in H3.3K27M Mutant Diffuse Intrinsic Pontine Glioma.Neurosurgery · 2020Article
- Article
- The expanding repertoire of targets for immune checkpoint inhibition in bladder cancer: What lies beneath the tip of the iceberg, PD-L1.Urologic oncology · 2018Review
- Antibody-drug conjugates in glioblastoma therapy: the right drugs to the right cells.Nature reviews. Clinical oncology · 2017Review
- Convection-Enhanced Delivery for Diffuse Intrinsic Pontine Glioma Treatment.Current neuropharmacology · 2017Article
- Recombinant Immunotoxin Therapy of Glioblastoma: Smart Design, Key Findings, and Specific Challenges.BioMed research international · 2017Review
- Humanized Affinity-matured Monoclonal Antibody 8H9 Has Potent Antitumor Activity and Binds to FG Loop of Tumor Antigen B7-H3.The Journal of biological chemistry · 2015Article
- The potential of theragnostic ¹²⁴I-8H9 convection-enhanced delivery in diffuse intrinsic pontine glioma.Neuro-oncology · 2014Article
- Immunotherapy in pediatric malignancies: current status and future perspectives.Future oncology (London, England) · 2014Review
- Identification of novel tumor-associated cell surface sialoglycoproteins in human glioblastoma tumors using quantitative proteomics.PloS one · 2014Article
- B7-H3, a potential therapeutic target, is expressed in diffuse intrinsic pontine glioma.Journal of neuro-oncology · 2013Article
- The future is now: chimeric antigen receptors as new targeted therapies for childhood cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2012Article
- Efficacy of interstitial continuous vincristine infusion in a bioluminescent rodent intracranial tumor model.Journal of neuro-oncology · 2012Article
- Glioblastoma multiforme: Molecular characterization and current treatment strategy (Review).Experimental and therapeutic medicine · 2012Article
Corrections and comments
- Erratum issuedKarempelas, Ioannis [corrected to Karampelas, Ioannis]
Authors and funding
11 authors at 4 institutions in 1 country.
Funding
Abstract
Monoclonal antibodies have the potential to target therapy for high-grade gliomas. Monoclonal antibody 8H9 is specific for membrane protein B7H3 and is reactive with most human high-grade gliomas. We tested the 8H9scFv-PE38 recombinant Pseudomonas immunotoxin in a preclinical model of high-grade glioma. The half maximal inhibitory concentration (IC(50)) of 8H9scFv-PE38 in vitro was determined using glioblastoma cell lines U87 and U251. Maximum tolerated infusion dose of 8H9scFv-PE38 following interstitial infusion to the striatum and pons was defined using athymic rats. Maximum tolerated infusion dose of 8H9scFv-PE38 or PBS control were interstitially delivered to athymic rats xenografted with U87 in the striatum or brain stem. Radiographic response and survivals were measured and compared between treatment groups. The in vitro IC(50) of 8H9scFv-PE38 for U87 was 1,265 ng/mL and, for U251, 91 ng/mL. The maximum tolerated infusion doses of interstitially infused 8H9scFv-PE38 to the striatum and brain stem were 0.75 and 1.8 mug, respectively. For rats harboring intracranial U87 xenografts, infusion of 8H9scFv-PE38 increased mean survival (striatum, 43.4 versus 24.6 days; brain stem, 80.6 versus 45.5 days; n = 28 total) and produced three long-term survivors past 120 days. None of the 14 placebo-treated animals survived >54 days. Tumors also showed volumetric response to infusion of 8H9scFv-PE38 by magnetic resonance imaging. Interstitial infusion of 8H9scFv-PE38 shows potential for the treatment of hemispherical and brain stem glioma. Mol Cancer Ther; 9(4); 1039-46. (c)2010 AACR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.